DoH Policies screened during the period: 1 October 2021 - 31 December 2021
Date published: 14 February 2022
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact
NICE Technology Appraisal TA725 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (review of TA579) (PDF 514KB)